Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
Merck
Dow
AstraZeneca

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 7,049,141

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,049,141
Title:Use of collagenase in the preparation of neural stem cell cultures
Abstract: The invention provides a method for using collagenase to dissociate neural stem cells in neural stem cell cultures. The collagenase treatment results in an increased cell viability and an increased number of proliferated neural stem cells over time.
Inventor(s): Uchida; Nobuko (Palo Alto, CA)
Assignee: StemCells California, Inc. (Palo Alto, CA)
Application Number:09/890,539
Patent Claims:1. A method for the in vitro proliferation of a neural stem cell culture comprising the steps of: (a) culturing a cell suspension containing one or more multipotent neural stem cells capable of producing progeny that are capable of differentiating into neurons and glia in a culture medium containing at least one proliferation-inducing growth factor to proliferate the neural stem cells to generate a neural stem cell culture comprising aggregated neural stem cells; and (b) passaging the cell culture in (a) by treating the culture with an amount of a collagenase preparation effective to dissociate the aggregated neural stem cells in the culture and passing the cell culture to a culture medium containing at least one proliferation-inducing growth factor to further proliferate the neural stem cell culture.

2. The method of claim 1 wherein the amount of the collagenase preparation is between 18 180 mU/ml.

3. The method of claim 1 wherein the amount of the collagenase preparation is between 54 126 mU/ml.

4. The method of claim 1 wherein the collagenase preparation further comprises at least one molecule selected from the group consisting of sulfhydryl protease, clostripain, aminopeptidase, or combinations thereof.

5. The method of claim 1 wherein the collagenase preparation is substantially pure, and contains minimal secondary proteolytic activity.

6. The process of claim 1, wherein the proliferation-inducing growth factor is selected from the group consisting of epidermal growth factor, amphiregulin, acidic fibroblast growth factor, basic fibroblast growth factor, transforming growth factor alpha, leukocyte inhibitory factor (LIF), glycostatin C and combinations thereof.

7. The method of claim 1 wherein the neural stem cell culture comprises genetically modified neural stem cells.

8. The method of claim 1, further comprising the step of differentiating the neural stem cell culture of (b) to produce a cell culture comprising differentiated neural cells selected from the group consisting of astrocytes, neurons, oligodendrocytes, and combinations thereof.

9. The method of claim 1 or claim 8, further comprising contacting the neural stem cell culture with a biological agent, and determining the effects of the biological agent on cells in the culture.

10. The method of claim 1 wherein the neural stem cell culture is a suspension culture.

11. The method of claim 1 wherein the neural stem cell culture is an adhesion culture.

12. The method of claim 1 wherein the neural stem cell culture comprises human neural stem cells.

13. A method for the in vitro proliferation of a neural stem cell culture wherein the percent viability of the cells in the culture is at least 60%, the method comprising the steps of: (a) culturing a cell suspension containing one or more multipotent neural stem cells capable of producing progeny that are capable of differentiating into neurons and glia in a culture medium containing at least one proliferation-inducing growth factor to proliferate the neural stem cells in (a) to generate a neural stem cell culture comprising aggregated neural stem cells; and (b) passaging the cell culture in (a) by treating the culture with an amount of a collagenase preparation effective to dissociate the aggregated neural stem cells in the culture and passing the cell culture to a culture medium containing at least one proliferation-inducing growth factor to further proliferate the neural stem cell culture.

14. The method of claim 13, wherein the percent viability of the cells in the culture is at least 75% after being passaged.

15. The method of claim 13, wherein the percent viability of the cells in the culture is at least 85% after being passaged.

16. The method of claim 13, wherein the amount of the collagenase preparation is between 18 180 mU/ml.

17. The method of claim 13, wherein the amount of the collagenase preparation is between 54 126 mU/ml.

18. The method of claim 13, wherein the collagenase preparation further comprises at least one molecule selected from the group consisting of sulfhydryl protease, clostripain, aminopeptidase, or combinations thereof.

19. The method of claim 13, wherein the collagenase preparation is substantially pure, and contains minimal secondary proteolytic activity.

20. The method of claim 13, wherein the neural stem cell culture comprises genetically modified neural stem cells.

21. The method of claim 13, further comprising the step of differentiating the neural stem cell culture of (b) to produce a cell culture comprising differentiated neural cells selected from the group consisting of astrocytes, neurons, oligodendrocytes, and combinations thereof.

22. The method of claim 13 wherein the neural stem cell culture is a suspension culture.

23. The method of claim 13 wherein the neural stem cell culture is an adhesion culture.

24. The method of claim 13 wherein the neural stem cell culture comprises human neural stem cells.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Merck
Express Scripts
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.